http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11400074-B1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6105a536310f65f95a9349f342567444
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B01D11-0492
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4015
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P17-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-6424
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D207-27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P41-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y304-21062
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4015
filingDate 2021-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e517008c10658ee131937cdc3e8e1715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_492495f577744319524311459237dcb9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c399105a8c0cae9a5b14379b1ca449ef
publicationDate 2022-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber US-11400074-B1
titleOfInvention Enzymatic process for the preparation of (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl]butyric acid and its conversion into brivaracetam
abstract A process for the preparation of Brivaracetam, an anti-convulsion drug, is provided comprising enzymatic conversion of (2RS)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid methyl ester selectively into (2S)-2-[(4R)-2-oxo-4-propyl-pyrrolidin-1-yl] butyric acid having high chiral purity, using protease from Bacillus licheniformis. Converting the chirally pure acid into amide results in Brivaracetam.
priorityDate 2021-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8338621-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0162726-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8957226-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID430818775
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478659926
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID447575892
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167622209
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID450686589
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478766137
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167679972
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID169423757
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID143425676
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID167704583
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426270916
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID44147317
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID478733717
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID86637443

Total number of triples: 37.